Canagliflozin, Dapagliflozin and Empagliflozin as Monotherapies for Treating Type 2 Diabetes (TA390)

Technology Appraisal Guidance No. 390

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Canagliflozin, dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:

  • a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and
  • a sulfonylurea or pioglitazone is not appropriate.

1.2 Adults whose treatment with canagliflozin, dapagliflozin or empagliflozin as monotherapy is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

Issue Date: May 2016

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in